Straits Times Index
3,332.35 -11.00 (-0.33%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,757.58 +41.11 (+0.23%) FTSE 100
8,179.68 -45.65 (-0.55%) Bitcoin USD
61,516.92 +857.69 (+1.41%) CMC Crypto 200
1,281.93 -1.90 (-0.15%)
Day One Biopharmaceuticals, Inc. (DAWN)
After hours:
| Previous close | 13.44 |
| Open | 13.46 |
| Bid | 13.81 x 200 |
| Ask | 13.87 x 200 |
| Day's range | 13.08 - 13.92 |
| 52-week range | 9.67 - 18.07 |
| Volume | |
| Avg. volume | 1,151,664 |
| Market cap | 1.209B |
| Beta (5Y monthly) | -1.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.50 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 35.63 |
GuruFocus.comInsider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
Director Saira Ramasastry sold 10,000 shares of Day One Biopharmaceuticals Inc (NASDAQ:DAWN) on June 21, 2024, as reported in a recent SEC Filing.
GlobeNewswireDay One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threat
FortuneExclusive: Day One Ventures closes its third fund at $150 million
Bucher’s Day One has closed its third fund at $150 million, Fortune can exclusively report. That far surpasses the firm’s original $100 million target, and I can only find one fund raised by a female solo GP this year that’s bigger.
